A method comprising: establishing a wireless connection between a first medical device and a second medical device, comprising: receiving, by the first medical device, via a short-range wireless technology protocol, connection information related to the second medical device; and establishing, by the first medical device, a wireless connection with the second medical device based on the connection information.

An intelligent bioelectric module for use with a drug delivery system has a case and a set of at least two electrodes in electrical communication with a detection surface of the case. The case is configured so that, in use, the detection surface comes into electrical communication with (i) a second surface of the delivery system when a first surface of the delivery system has been put into contact with a tissue surface of a human or animal subject or (ii) the tissue surface that is adjacent to a portion contacted by the first surface of the delivery system or (iii) both the second surface and the tissue surface.

Apparatus and methods are described for use with a portion of plant material that includes at least one active ingredient. A vaporizing unit includes a heating element configured to heat the plant material, and a sensor configured to detect an indication of airflow rate through the vaporizing unit. Control circuitry is configured to receive an indication of the airflow rate through the vaporizing unit, and, in response thereto, to determine a smoking profile that is desired by the user. The control circuitry drives the heating element to vaporize the active ingredient of the plant material by heating the plant material according to the determined smoking profile. The control circuitry dynamically updates the smoking profile in response to changes in airflow rate over the course of a smoking session. Other applications are also described.

A control body is coupled or coupleable with a cartridge that is equipped with a heating element and contains an aerosol precursor composition, the control body and cartridge forming an aerosol delivery device. The control body includes a control component to control the heating element to activate and vaporize components of the aerosol precursor composition. The control body also includes a gas sensor configured to detect a presence of gas in an environment of the control body, and the gas sensor or control component are further configured to control operation of at least one functional element of the aerosol delivery device in response to the presence of gas so detected.

A device and method of generating an enriched gas within a nasal vestibule of a patient includes a housing, a chamber, a chamber inlet, a pump, a molecular sieve bed, a release outlet, and a breath duct. The chamber is configured to be received within the nasal vestibule. The pump is configured to direct an ambient air from an ambient environment into the chamber. The molecular sieve bed is positioned within the chamber and configured to collect a predetermined molecule from the ambient air thereby generating the enriched gas. The release outlet is configured to discharge the enriched gas from the chamber into the nasal vestibule. The breath duct longitudinally extends through the housing such that the breath duct is configured to fluidly communicate a fluid flow through the housing for nasal breathing by the patient while the chamber is positioned within the nasal vestibule.

An oscillating positive expiratory pressure system including an oscillating positive expiratory pressure device having a chamber, an input component in communication with the chamber, wherein the input component is operative to sense a flow and/or pressure and generate an input signal correlated to the flow or pressure, a processor operative to receive the input signal from the input component and generate an output signal, and an output component operative to receive the output signal, and display an output.

The present disclosure provides an aerosol precursor consumable, and an aerosol delivery device that comprises a control unit that defines a receiving chamber, and a removable and replaceable aerosol precursor consumable, at least a portion of the consumable configured to be received into the receiving chamber. The aerosol precursor consumable comprises a housing defining an outer wall, an aerosol precursor composition reservoir located in the housing and configured to contain an aerosol precursor composition, an atomizer located in the housing, and at least one aroma diffuser. The atomizer is configured to vaporize the aerosol precursor composition to generate an aerosol for oral delivery to a user, and the at least one aroma diffuser is configured to diffuse an aroma composition for olfactory delivery to the user.

A method of administering insulin includes receiving glucose measurements of a patient at a data processing device from a continuous glucose monitoring system. The glucose measurements are separated by a time interval. The method also includes receiving patient information at the data processing device and selecting a subcutaneous insulin treatment from a collection of subcutaneous insulin treatments. The selection is based on the glucose measurements and the patient information. The selection includes one or more of a subcutaneous standard program, a subcutaneous program without meal boluses, a meal-by-meal subcutaneous program without carbohydrate counting, a meal-by-meal subcutaneous program with carbohydrate counting, and a subcutaneous program for non-diabetic patients. The method also includes executing, using the data processing device, the selected subcutaneous insulin treatment.

An infusion pump system providing therapy to a patient in a closed-loop or semi-closed loop mode can safely automatically revert to open-loop therapy. The system stores a default open-loop basal rate profile in memory. The system also continually tracks the insulin on board for the patient over a plurality of closed-loop therapy intervals. When an error or event occurs requiring reversion to open-loop therapy, the system automatically provides therapy according to the open-loop basal rate profile and the tracked insulin on board amount.

A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and/or a detected location of the user.